loading...| Preferred Name |
paricalcitol |
|
| Synonyms |
Zemplar |
|
| Definitions |
A synthetic noncalcemic, nonphosphatemic vitamin D analogue. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C38693" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38693" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000315740 |
|
| altLabel |
Zemplar |
|
| cui |
C0724464 C0249582 |
|
| DATE FIRST PUBLISHED |
2003-06-23 |
|
| Date last modified |
2006-05-10 |
|
| definition |
A synthetic noncalcemic, nonphosphatemic vitamin D analogue. Paricalcitol binds to the vitamin D receptor and has been shown to reduce parathyroid hormone (PTH) levels. This agent also increases the expression of PTEN ('Phosphatase and Tensin homolog deleted on chromosome Ten'), a tumor-suppressor gene, in leukemic cells and cyclin-dependent kinase inhibitors, resulting in tumor cell apoptosis and tumor cell differentiation into normal phenotypes. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C38693" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38693" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C38693 |
|
| notation |
CDR0000315740 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
paricalcitol |
|
| tui |
T109 T127 T121 |